Successful Retreatment of Glecaprevir‐Pibrentasvir for Hepatitis C Virus Genotype 2a Infection in Patient Whose Cirrhosis Improved From Decompensation to Compensation After Sofosbuvir–Velpatasvir Therapy

Documenti analoghi

• Long‐Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus‐Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort Study
  di: Satoru Kakizaki, et al.
  Pubblicazione: (2026)
• Injecting Drug Use History and Younger Age Worsen Adherence to Scheduled Hospital Visits in Glecaprevir and Pibrentasvir Therapy for Chronic Hepatitis C
  di: Seiichi Tawara, et al.
  Pubblicazione: (2026)
• Efficacy and Safety of Glecaprevir/Pibrentasvir in Children Aged 3–11 Years With Chronic Hepatitis C: A Real‐World, Prospective, Multicenter Study in Japan
  di: Tatsuki Mizuochi, et al.
  Pubblicazione: (2025)
• Lobe‐Based Hepatic Uptake Index of Gd‐EOB‐DTPA on Contrast‐Enhanced MRI to Quantitatively Discriminate between Compensated and Decompensated Hepatitis B‐Related Cirrhosis
  di: Fulin Lu, et al.
  Pubblicazione: (2024)
• A Rare, Atypical Presentation of Decompensated Cirrhosis: Isolated Transudative Hepatic Chylothorax Without Ascites
  di: Michael Yulong Wu, et al.
  Pubblicazione: (2025)